Cargando…

Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1

We have recently shown that induction of the p53 tumour suppressor protein by the small-molecule RITA (reactivation of p53 and induction of tumour cell apoptosis; 2,5-bis(5-hydroxymethyl-2-thienyl)furan) inhibits hypoxia-inducible factor-1α and vascular endothelial growth factor expression in vivo a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, A, Yang, J, Maya-Mendoza, A, Jackson, D A, Ashcroft, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122121/
https://www.ncbi.nlm.nih.gov/pubmed/21593792
http://dx.doi.org/10.1038/cddis.2011.42
_version_ 1782206899912966144
author Ahmed, A
Yang, J
Maya-Mendoza, A
Jackson, D A
Ashcroft, M
author_facet Ahmed, A
Yang, J
Maya-Mendoza, A
Jackson, D A
Ashcroft, M
author_sort Ahmed, A
collection PubMed
description We have recently shown that induction of the p53 tumour suppressor protein by the small-molecule RITA (reactivation of p53 and induction of tumour cell apoptosis; 2,5-bis(5-hydroxymethyl-2-thienyl)furan) inhibits hypoxia-inducible factor-1α and vascular endothelial growth factor expression in vivo and induces p53-dependent tumour cell apoptosis in normoxia and hypoxia. Here, we demonstrate that RITA activates the canonical ataxia telangiectasia mutated/ataxia telangiectasia and Rad3-related DNA damage response pathway. Interestingly, phosphorylation of checkpoint kinase (CHK)-1 induced in response to RITA was influenced by p53 status. We found that induction of p53, phosphorylated CHK-1 and γH2AX proteins was significantly increased in S-phase. Furthermore, we found that RITA stalled replication fork elongation, prolonged S-phase progression and induced DNA damage in p53 positive cells. Although CHK-1 knockdown did not significantly affect p53-dependent DNA damage or apoptosis induced by RITA, it did block the ability for DNA integrity to be maintained during the immediate response to RITA. These data reveal the existence of a novel p53-dependent S-phase DNA maintenance checkpoint involving CHK-1.
format Online
Article
Text
id pubmed-3122121
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-31221212011-07-05 Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1 Ahmed, A Yang, J Maya-Mendoza, A Jackson, D A Ashcroft, M Cell Death Dis Original Article We have recently shown that induction of the p53 tumour suppressor protein by the small-molecule RITA (reactivation of p53 and induction of tumour cell apoptosis; 2,5-bis(5-hydroxymethyl-2-thienyl)furan) inhibits hypoxia-inducible factor-1α and vascular endothelial growth factor expression in vivo and induces p53-dependent tumour cell apoptosis in normoxia and hypoxia. Here, we demonstrate that RITA activates the canonical ataxia telangiectasia mutated/ataxia telangiectasia and Rad3-related DNA damage response pathway. Interestingly, phosphorylation of checkpoint kinase (CHK)-1 induced in response to RITA was influenced by p53 status. We found that induction of p53, phosphorylated CHK-1 and γH2AX proteins was significantly increased in S-phase. Furthermore, we found that RITA stalled replication fork elongation, prolonged S-phase progression and induced DNA damage in p53 positive cells. Although CHK-1 knockdown did not significantly affect p53-dependent DNA damage or apoptosis induced by RITA, it did block the ability for DNA integrity to be maintained during the immediate response to RITA. These data reveal the existence of a novel p53-dependent S-phase DNA maintenance checkpoint involving CHK-1. Nature Publishing Group 2011-05 2011-05-19 /pmc/articles/PMC3122121/ /pubmed/21593792 http://dx.doi.org/10.1038/cddis.2011.42 Text en Copyright © 2011 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Original Article
Ahmed, A
Yang, J
Maya-Mendoza, A
Jackson, D A
Ashcroft, M
Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1
title Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1
title_full Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1
title_fullStr Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1
title_full_unstemmed Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1
title_short Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1
title_sort pharmacological activation of a novel p53-dependent s-phase checkpoint involving chk-1
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122121/
https://www.ncbi.nlm.nih.gov/pubmed/21593792
http://dx.doi.org/10.1038/cddis.2011.42
work_keys_str_mv AT ahmeda pharmacologicalactivationofanovelp53dependentsphasecheckpointinvolvingchk1
AT yangj pharmacologicalactivationofanovelp53dependentsphasecheckpointinvolvingchk1
AT mayamendozaa pharmacologicalactivationofanovelp53dependentsphasecheckpointinvolvingchk1
AT jacksonda pharmacologicalactivationofanovelp53dependentsphasecheckpointinvolvingchk1
AT ashcroftm pharmacologicalactivationofanovelp53dependentsphasecheckpointinvolvingchk1